Cefmenoxime
Cefmenoxime is a third-generation cephalosporin antibiotic.
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intramuscular, intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 100% (given IM) |
| Protein binding | 50% to 70% |
| Metabolism | Negligible |
| Elimination half-life | 1 hour |
| Excretion | Kidney, unchanged |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H17N9O5S3 |
| Molar mass | 511.55 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Synthesis
The alkylation of ethyl 2-hydroxyimino-3-oxobutanoate [5408-04-8][66508-93-8] (1) with dimethylsulfate gives Ethyl (2Z)-2-methoxyimino-3-oxo-butanoate [60846-14-2] (2). Halogenation with molecular bromine leads to ethyl 4-bromo-2-methoxyimino-3-oxobutanoate [60845-87-6] (3). Treatment with thiourea led to Ethyl (Z)-2-(2-amino-4-thiazolyl)-2-methoxyiminoacetate [64485-88-7] [60846-15-3] (4). Amide formation with chloroacetyl chloride gave PC6372031 (5). Saponification with potassium hydroxide gave PC5371531 (6). Halogenation with phosphorus pentachloride gave PC12884126 (7). Amide formation with PC15573427 (8) gave PC53669018 (9). Removal of the protecting group with Benzyltriethylammonium bromide [5197-95-5] furnished PC54254231 (10). The tert-butyl ester was deprotected with trifluoroacetic acid giving PC53850835 (11). Lastly, thioether formation with 5-Mercapto-1-methyltetrazole [13183-79-4] (12) completed the synthesis of Cefmenoxime (13).
References
- Serradell, M.N.; Castaer, J.; Blancafort, P.; SCE-1365. Drugs Fut 1980, 5, 3, 146.
- Ochiai M, Aki O, Morimoto A, Okada T, Matsushita Y. New cephalosporin derivatives with high antibacterial activities. Chem Pharm Bull (Tokyo). 1977 Nov;25(11):3115-7. doi: 10.1248/cpb.25.3115. PMID: 603968.
- Ochiai M, Morimoto A, Miyawaki T, Matsushita Y, Okada T, Natsugari H, Kida M. Synthesis and structure-activity relationships of 7 beta-[2-(2-aminothiazol-4-yl)acetamido]cephalosporin derivatives. V. Synthesis and antibacterial activity of 7 beta-[2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-cephalosporin derivates and related compounds. J Antibiot (Tokyo). 1981 Feb;34(2):171-85. doi: 10.7164/antibiotics.34.171. PMID: 6271716.
- Ochiai M, Morimoto A, Miyawaki T. Synthesis and structure-activity relationships of 7 beta-[2-(2-aminothiazol-4-yl)acetamido]cephalosporin derivatives. VI. Alternative syntheses of 7 beta-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]cephalosporin derivatives. J Antibiot (Tokyo). 1981 Feb;34(2):186-92. doi: 10.7164/antibiotics.34.186. PMID: 6271717.
- Michihiko Ochiai, et al. U.S. patent 4,098,888 (1978 to Takeda Pharmaceutical Co Ltd).
- Japan. Pat., 80 38 349, (1980); CA, 93, 204670
External links
- Diseases Database (DDB): 30892
- Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T (1995). "Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis". Jpn J Antibiot. 48 (5): 602–9. PMID 7637194.
- Paladino J, Fell R (1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia". Ann Pharmacother. 28 (3): 384–9. doi:10.1177/106002809402800316. PMID 8193431. S2CID 29444681.
- Duncker G, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture". Ophthalmologica. 208 (5): 262–6. doi:10.1159/000310505. PMID 7816419.